Global Pyrimethamine Market – Industry Trends and Forecast to 2029

Pyrimethamine Market Analysis and Size

Pyrimethamine is considered one of the most important medications by World Health Organization’s list of essential medicines. The ability of pyrimethamine to cure protozoan infection and toxoplasma infections, increasing number of HIV positive patients worldwide and immunosuppressed individual at a risk of infections are the major factors driving the pyrimethamine treatment market during the forecast period.

Data Bridge Market Research analyses a growth rate in the global pyrimethamine market in the forecast period 2022-2029. The expected CAGR of global pyrimethamine market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 1.51 billion in 2021, and it would grow upto USD 2.32 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Pyrimethamine Market Scope and Segmentation

Market Definition

Pyrimethamine is one of the antagonists of folic acid that is used as an antimalarial or with a sulphonamide to treat toxoplasmosis. Pyrimethamine impedes plasmodia dihydrofolate reductase as it blocks the biosynthesis of purines and pyrimidines, that are essential for DNA synthesis and cell multiplication. This process leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver. It is usually used as an adjunct in the treatment of uncomplicated, chloroquine resistant, P. falciparum malaria.  

Global Pyrimethamine Market Dynamics

Drivers

• Increase in HIV cases

As per the global HIV statistics published by The Joint United Nations Programme on HIV/AIDS, in 2020, worldwide, there were 37.7 million people living with HIV, out of which 36.0 million were adults, 1.7 million were children aged between 0-14 years, and 53% of all people living with HIV were women and girls. This boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is projected to boost the market growth. The segment is anticipated to accelerate the global market as most products are available in capsule and tablet form and it is a very convenient route of administration.

Opportunities

• Increasing Drug Development and Research Activities

Technological advancements and rapid innovation in drug discovery and development, especially in personalized medicine, create significant opportunities for manufacturers in the global pyrimethamine market. This is another factor expected to drive growth of the global pyrimethamine market.  

• Increasing Cases of Toxoplasmosis

According to The Centers for Disease Control and Prevention (CDC), toxoplasmosis is one of the five neglected parasitic infections in the U.S. It is the second leading cause of death from foodborne illness in the country and more than 60 million people in the U.S. carry the toxoplasma parasite, and more than one million people in the U.S. are infected yearly with the toxoplasma parasite, that is associated with high rates of morbidity and mortality.

 Restraints/Challenges

• Side Effects of Aminophylline

The certain side effects which may occur with pyrimethamine medication include allergic reactions, tongue changes, blood in the urine, heart rhythm disorders, blood disorders, anorexia, and vomiting that act as a restraining factor for the growth of this market.

• High Cost

The huge expenditure associated with these agents hamper the market growth.

This global pyrimethamine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pyrimethamine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Pyrimethamine Market             

COVID-19 has left a major global public health crisis that has impacted practically every sector, and its long-term consequences are expected to have an influence on industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and much delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are projected to witness a huge future growth because of the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the global pyrimethamine market.

Global Pyrimethamine Market Scope

The global pyrimethamine market is segmented on the basis of indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indications

• Malaria
• Toxoplasmosis
• Others

Route of Administration

• Oral

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Pyrimethamine Market Regional Analysis/Insights

The global pyrimethamine market is analyzed and market size insights and trends are provided by indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global pyrimethamine market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global pyrimethamine market throughout the forecasted period due to increased government awareness programs, increased prevalence of malaria & AIDS.  

North America dominates the market due to the presence of key manufacture of the product, high research & development, healthcare expenditure, and skilled professionals.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Pyrimethamine Market Share Analysis

The global pyrimethamine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pyrimethamine market

Key players operating in the global pyrimethamine market include:

• Bayer AG (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Hikma Pharmaceutical PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.K.)
• Aurobindo Pharma (India)
• Vyera Pharmaceuticals, LLC (Switzerland)
• CEROVENE INC HEALTHCARE PVT.LTD (India)
• Amneal Pharmaceuticals LLC (U.S.)
• PRN (U.S.)
• TargetMol Chemicals Inc. (U.S.)

SKU-55259